Health
Understanding a Treatment Option for Advanced Kidney Cancer

(Family Features) When kidney cancer spreads or becomes advanced, it can be challenging to treat. Common signs and symptoms can include blood in urine, lower back pain on one side, a mass on the side or lower back, loss of appetite or unexplained weight loss.
While a diagnosis of advanced kidney cancer can be overwhelming, there are steps patients can take to feel more empowered as they face the disease, starting with learning about the treatments that may be available for them.
Exploring Your Options
When facing advanced kidney cancer, it’s important for patients and caregivers to have open communication with their healthcare team to understand the diagnosis and establish a treatment plan.
Asking questions to understand where the cancer has spread, what the expected prognosis is and the potential benefits of treatment – including the possibility to live longer – can be critical to aligning on a path forward.
Fortunately, there are several types of medicines available for advanced kidney cancer today, depending on the specifics of each patient’s disease. Chemotherapy, targeted therapy or immunotherapy are a few types of treatment that may be considered, sometimes in combination. Immunotherapy works differently than chemotherapy or targeted therapy, as it helps a person’s own immune system to fight cancer and can enable the immune system to find and attack cancer cells. For some patients, dual immunotherapy – or a combination of two immunotherapy treatments – may be recommended.
For example, Opdivo (nivolumab) + Yervoy (ipilimumab) is approved by the U.S. Food and Drug Administration (FDA) as a combination of two immunotherapies for certain newly diagnosed adults whose kidney cancer (also referred to as renal cell carcinoma) has spread. It is not known if Opdivo is safe and effective in children younger than 18 years of age. Opdivo (10 mg/mL) and Yervoy (5 mg/mL) are injections for intravenous use.
This combination of two immunotherapies has the potential to work with the immune system in different but complementary ways to help fight cancer. While Yervoy may stimulate the kind of cells that help fight cancer, Opdivo may help these cells find and fight the cancer cells again.
While doing so, this immunotherapy combination can also affect healthy cells. These problems can sometimes become serious or life threatening and can lead to death. These problems may happen anytime during treatment or even after treatment has ended. You may have more than one of these problems at the same time. Some of these problems may happen more often when Opdivo is used in combination with Yervoy.
Opdivo and Yervoy can cause problems that can sometimes become serious or life-threatening and can lead to death. Serious side effects may include lung problems; intestinal problems; liver problems; hormone gland problems; kidney problems; skin problems; eye problems; problems in other organs and tissues; severe infusion reactions; and complications of stem cell transplant, including graft-versus-host disease (GVHD), that uses donor stem cells (allogeneic). Call or see your healthcare provider right away for any new or worsening signs or symptoms. Please see additional Important Safety Information below.
Understanding Overall Survival
One of the most important considerations for choosing a treatment is the potential for survival, or the chance to live longer. Overall survival is sometimes reported as a survival rate, which is the percentage of people in a clinical trial who are still alive for a certain time period after being diagnosed with or starting treatment for a disease, such as cancer.
“After my cancer diagnosis, my wife and I prayed about our future and pursuing every avenue with that goal in mind,” said Terry Broussard, who has been living with advanced kidney cancer. “I wanted a treatment that may give me a chance to live longer in order to see my youngest child graduate high school.”
Broussard’s doctor recommended treatment with Opdivo + Yervoy, which has overall survival data at five years. The FDA approval of this dual immunotherapy in advanced renal cell carcinoma (RCC) was based on results from the CheckMate -214 clinical trial, which included 847 previously untreated patients with kidney cancer that had spread and with one or more risk factors.
In the primary analysis at two years (25.2 months), the length of time patients lived without tumors worsening was 11.6 months for this immunotherapy combination and 8.4 months for sunitinib. There was no meaningful difference between the two treatments.
Researchers also assessed the overall response rate, which is a measure of the percentage of patients whose cancer shrunk (partial response) or disappeared completely (complete response) after treatment.
At the two-year time point, 41.6% of patients treated with Opdivo + Yervoy (95% CI:36.9-46.5) responded to treatment (n=177/425) versus 26.5% (n=112/422) of those treated with sunitinib (95% CI:22.4-31.0). Partial tumor shrinkage occurred in 32.2% of the patients treated with this immunotherapy combination compared to 25.4% of those treated with sunitinib. Tumors disappeared completely in 9.4% of patients treated with this immunotherapy combination versus in 1.2% of patients treated with sunitinib. The disappearance of any measurable tumors in response to treatment does not necessarily mean the cancer has been cured. Opdivo + Yervoy will not work for everyone. Individual results may vary.
“Advanced kidney cancer is a complex disease with many treatment options, which can feel overwhelming for people facing a devastating cancer diagnosis,” said Ulka Vaishampayan, M.D., professor, Internal Medicine, Division of Hematology/Oncology, University of Michigan. “The goal of treatment is to help patients live longer, and research like these five-year data gives us insight into what treatment with Opdivo + Yervoy may look like for patients from the trial over time.”
The most common side effects of Opdivo, when used in combination with Yervoy, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection; headache; low thyroid hormone levels (hypothyroidism); constipation; decreased weight; and dizziness.
Establishing and Leaning on a Support System
From diagnosis to treatment and beyond, many patients find the support from family, friends and loved ones invaluable. Identifying a friend, spouse or caregiver who can join doctor appointments, ask questions and take notes can be a helpful way to track all the details that can often be overwhelming when facing cancer. “I’ve been incredibly lucky to have the support of my wife, children, nurses and doctors every step of the way,” said Broussard. “Even in the most challenging moments, knowing they were by my side gave me the hope and inspiration I needed to continue moving forward.”
To learn more, visit Opdivo.com.
Source: Bristol Myers Squibb
Photo caption: Terry Broussard and his wife, Tracy. Broussard is an actual patient who has been compensated by Bristol Myers Squibb for his time.
INDICATION AND IMPORTANT SAFETY INFORMATION
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with kidney cancer in certain people when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
It is not known if OPDIVO is safe and effective in children younger than 18 years of age.
Information provided in this article is not a substitute for talking with your healthcare professional. Your healthcare professional is the best source of information about your disease.
Important Safety Information for OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
What is the most important information I should know about OPDIVO + YERVOY?
OPDIVO and YERVOY are medicines that may treat certain cancers by working with your immune system. OPDIVO and YERVOY can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time. Some of these problems may happen more often when OPDIVO is used in combination with another therapy.
What are the serious side effects of OPDIVO + YERVOY?
Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:
- Lung problems: new or worsening cough; shortness of breath; chest pain
- Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; severe stomach-area (abdominal) pain or tenderness
- Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); bleeding or bruising more easily than normal
- Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heart beat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
- Kidney problems: decrease in your amount of urine; blood in your urine; swelling in your ankles; loss of appetite
- Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in the mouth or nose, throat, or genital area
- Eye problems: blurry vision, double vision, or other vision problems; eye pain or redness.
Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with OPDIVO and YERVOY. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:
- Chest pain; irregular heart beat; shortness of breath; swelling of ankles
- Confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs
- Double vision; blurry vision; sensitivity to light; eye pain; changes in eye sight
- Persistent or severe muscle pain or weakness; muscle cramps
- Low red blood cells; bruising
Getting medical help right away may help keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment and may treat you with corticosteroid or hormone replacement medicines. Your healthcare team may also need to delay or completely stop your treatment if you have severe side effects.
Possible side effects of OPDIVO + YERVOY
OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:
- See “What is the most important information I should know about OPDIVO + YERVOY?”
- Severe infusion reactions. Tell your healthcare team right away if you get these symptoms during an infusion of OPDIVO or YERVOY: chills or shaking; itching or rash; flushing; shortness of breath or wheezing; dizziness; feel like passing out; fever; back or neck pain
- Complications, including graft-versus-host disease (GVHD), of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO or YERVOY. Your healthcare provider will monitor you for these complications.
The most common side effects of OPDIVO, when used in combination with YERVOY, include: feeling tired; diarrhea; rash; itching; nausea; pain in muscles, bones, and joints; fever; cough; decreased appetite; vomiting; stomach-area (abdominal) pain; shortness of breath; upper respiratory tract infection; headache; low thyroid hormone levels (hypothyroidism); constipation; decreased weight; and dizziness.
These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA- 1088.
Before receiving OPDIVO or YERVOY, tell your healthcare provider about all of your medical conditions, including if you:
- have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
- have received an organ transplant
- have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
- have received radiation treatment to your chest area in the past and have received other medicines that are like OPDIVO
- have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
- are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if OPDIVO or YERVOY passes into your breast milk. Do not breastfeed during treatment with OPDIVO or YERVOY and for 5 months after the last dose of OPDIVO or YERVOY.
Females who are able to become pregnant:
Your healthcare provider should do a pregnancy test before you start receiving OPDIVO or YERVOY.
- You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of OPDIVO or YERVOY. Talk to your healthcare provider about birth control methods that you can use during this time.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with OPDIVO or YERVOY. You or your healthcare provider should contact Bristol-Myers Squibb at 1-844-593-7869 as soon as you become aware of a pregnancy.
Tell your healthcare provider about all the medicines you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.
Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO and YERVOY.
© 2023 Bristol-Myers Squibb Company. All Rights Reserved.
OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.
7356-US-2200719 2/23
SOURCE:
Bristol Myers Squibb
https://stmdailynews.com/category/lifestyle/health-and-wellness/
Health
Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it
Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health. Despite radon being the second-leading cause of lung cancer, many have never tested their home for it.

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it
(Sheeka Sanahori) Avoid tobacco products. Eat a healthy diet. Get recommended cancer screenings. Most U.S. adults recognize these behaviors as ways to lower their cancer risk or catch cancer early. Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health.
But U.S. adults are far less likely to recognize a risk factor they can’t control through daily habits. Radon – an odorless, invisible gas that forms naturally in the ground – is the second leading cause of lung cancer, but new research from the Prevent Cancer Foundation finds that 8 in 10 U.S. adults have never tested their home for radon. The findings are based on the Foundation’s annual Early Detection Survey of more than 7,000 U.S. adults, conducted in January 2026.
With recent high-profile lung cancer cases, such as the October diagnosis of Pope Leo XIV, who is not known to have a history of smoking cigarettes, more people are paying attention to other risk factors for lung cancer, especially for people who have never smoked.
Testing for radon is last on the list
When asked about preventive behaviors, 77.5% say avoiding tobacco lowers their cancer risk. Three out of four say eating a healthy diet and getting routine cancer screenings make a difference, too. More than half also named regular exercise, limiting alcohol and protecting themselves from harmful UV rays.
Testing their home for radon ranked last on the list of preventive behaviors, with only 28% listing it as a way to reduce their cancer risk.
Most homes go untested in every region
Radon hasn’t reached the same level of public awareness as tobacco use, diet and exercise. U.S. adults appear to overlook an environmental risk that could be inside their own homes. Eighty percent of U.S. adults report never having their homes tested for radon, and only 12% have tested within the last five years. The U.S. Environmental Protection Agency (EPA) recommends testing every two years.
In the Northeast, about 7 in 10 people (72%) have never tested their home for radon. That percentage increases for the Midwest (79%), West (82%) and South (83%). Unlike cigarettes, radon does not produce smoke and is odorless, so a test is the only way to detect its presence.
What it takes to find out
Radon can enter homes through the ground when uranium underneath decays. Once it’s inside, it gets trapped. People can live with high radon levels without knowing it, in older homes and new construction alike. Breaking ground on undisturbed land during construction can release more radon.
Renters can either test themselves or ask their landlord whether the home has been tested and request the results. Landlord requirements vary by state.
Test kits are inexpensive and available online and at home improvement stores. The EPA recommends taking action to reduce radon levels at 4 picocuries per liter (pCi/L) or higher, and notes that levels below that may still carry risk. If levels are high, a mitigation system can bring them down.
Beyond radon, the EPA and other health authorities cite avoiding tobacco and secondhand smoke as the most significant steps people can take to lower lung cancer risk, along with following screening guidelines based on personal risk factors.
Methodology
The Prevent Cancer Foundation commissioned Atomik Research to conduct the Foundation’s fourth annual Early Detection Survey of U.S. adults. The study consists of an online survey questionnaire, which includes several repeated measures from a previous year’s questionnaire and a primary data set gathered from a sample of 7,510 adults located throughout the United States. The sample consists of adults 21 years of age or older, and researchers implemented several demographic-based quotas in order to achieve sample characteristics similar to the overall U.S. population of adults 21 and older.
Researchers controlled for demographic variables such as biological sex, age group classification, race/ethnicity, parental status, geographic region, employment status and community classifications (e.g., urban or rural classification).
The margin of error of the overall sample is +/-1 percentage point with a confidence level of 95%. Fieldwork took place between Jan. 10 and Jan. 30, 2026. Atomik Research is an independent market research agency.
Percentages may not add up to 100% due to computer rounding, and/or the acceptance of multiple responses.
Photo courtesy of Shutterstock (family playing)
SOURCE:
Prevent Cancer Foundation
Women's Health
Menopause changes your mouth. Most women have no idea.
Menopause changes your mouth: Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

Menopause changes your mouth. Most women have no idea.
(Sheeka Sanahori) Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.
There’s a name for it: menopause mouth. According to survey data from Delta Dental Insurance Company, 83% of women 40 and older in menopause aren’t aware of any of its symptoms.
What menopause mouth feels like
Forty percent say they have noticed an increase in dry mouth. Another 27% have noticed more tooth sensitivity in recent months, and 26% say things taste different than they used to. You tell yourself it’s something else. You’re not drinking enough water; you’ve been brushing too hard. Menopause isn’t the first thing that comes to mind.
It adds up. Forty-five percent say oral symptoms associated with menopause, such as tooth pain, dry mouth or gum inflammation, take a toll on their confidence, mood or mental health.
Menopause affects the whole body, mentally and physically. So why is the mouth left out?
Even after learning about this connection, 30% of women say they can’t find information about menopause-related oral health concerns. It isn’t that no one is willing to discuss it.
What makes the conversation hard to start
Three-quarters of dentists say they are comfortable discussing menopause with patients. They just want to know who they’re talking to. Most say they would want more patient history, or to know a patient was in menopause, before raising the subject. Forty-five percent say they would not bring up how menopause affects oral health unless a patient asked.
Dentists also believe that patients are already informed. Ninety-four percent say their patients are at least somewhat aware that menopause can affect oral health. So a patient says nothing about her dry mouth, because it doesn’t seem like a dental problem. The dentist doesn’t bring it up either, assuming someone already has.
Women are asking for the information
Nearly nine in 10 women say it would help to receive specific instructions during dental visits about managing oral health during menopause. And 69% say they would be more likely to book an appointment if a primary care provider or OB-GYN had told them menopause affects oral health.
No matter who brings it up, the conversation is one worth having. Hormonal changes during menopause can increase the risk of tooth loss or tooth decay, gum disease, receding gumline or loss of jawbone density. Discussing new oral symptoms with a dentist can help women identify potential problems and address them early.
How to start the conversation with your dentist
Your dentist probably doesn’t know you’re in menopause. Start there.
Questions worth asking:
- “Could the changes I’m noticing be related to menopause?”
- “I haven’t had a cavity in 30 years, and now I have two. Could that be tied to hormonal changes?”
- “What can I do about dry mouth?”
- “Are there symptoms I should watch for?”
- “Should I adjust my oral care routine?”
Any one of these questions can get the conversation started.
Methodology
Delta Dental Insurance Company commissioned Atomik Research to conduct two online surveys between June 25 and July 2, 2025.
The first surveyed 200 dentists throughout the United States. The margin of error is +/- 7 percentage points with a 95% confidence level.
The second surveyed 1,511 women ages 40 or older throughout the United States. To qualify, participants had to indicate they are in perimenopause, menopause or post-menopause. Those who were not sure which stage they were in, or who indicated they were not yet in one of the three stages, were excused from participation. The margin of error is +/- 3 percentage points with a 95% confidence level
Atomik Research, part of 4media group, is an independent market research agency.
Photo courtesy of Shutterstock
SOURCE:
Delta Dental Insurance Company
health and wellness
Flu Season Arrives Early: Walgreens Launches 2026-2027 Flu Index as Activity Rises Across the U.S.
The 2026-2027 flu season is tracking four weeks ahead of recent years. Explore Walgreens’ new Flu Index, rising activity, and ways to stay protected.
Last Updated on November 6, 2026 by Daily News Staff
2026-2027 Flu Season: New tracking data suggests influenza activity is running approximately four weeks ahead of recent seasons, with increases reported across western states and Florida.
2026-2027 Flu Season Starts Early as Walgreens Launches New Flu Index
STM Daily News | Health & Wellness
October 30, 2026
Flu season may be getting an early start this year, and a new online tracking tool from Walgreens is giving Americans a closer look at respiratory illness activity in their communities.
On October 21, Walgreens announced the launch of its 2026-2027 Flu Index, an interactive tool that monitors influenza, COVID-19, and other acute respiratory illnesses across the United States.
According to the company’s initial findings, national flu activity is tracking approximately four weeks ahead of recent flu seasons, with increasing activity reported across several western states and Florida.
The early trends serve as a reminder that influenza doesn’t necessarily wait until winter to begin spreading.
Flu Activity Is Increasing Earlier Than Expected
Walgreens reports that its early-season data indicates influenza activity is already increasing in multiple parts of the country.
The company’s findings include:
- Earlier flu activity: National flu activity is tracking approximately four weeks ahead of recent seasons.
- Regional increases: Several western states and Florida are experiencing rising activity.
- More antiviral prescriptions: Walgreens reports dispensing more flu antiviral medications than during the same period in 2025.
- Growing demand for cold and flu products: Sales of cold and flu medications, at-home respiratory illness tests, cough drops, and tea have increased by double-digit percentages compared with last year.
Although these indicators suggest respiratory illness activity is increasing, they do not necessarily mean the current flu season will be more severe than previous seasons.
Increased purchases of cold medications and testing products can reflect changes in consumer behavior as well as illness trends.
The findings come from Walgreens’ pharmacy and retail data and should be considered alongside public health surveillance from the Centers for Disease Control and Prevention (CDC).
What Is the Walgreens Flu Index?
The Walgreens Flu Index is an interactive online platform designed to help consumers understand where respiratory illnesses are circulating and how activity is changing over time.
The tool combines several types of information, including:
- Flu and COVID-19 testing data from Walgreens locations
- Prescription antiviral medication trends
- Over-the-counter cold and flu product purchases
- Geographic patterns in respiratory illness activity
Using these indicators, Walgreens calculates an activity score ranging from 0 to 10.
A score of zero represents the lowest level of activity, while a score of ten represents the highest.
The index provides weekly information for states and territories, along with more than 1,500 counties where sufficient Walgreens data is available.
The map is updated every Monday, allowing users to compare current activity with previous weeks and the prior flu season.
Importantly, Walgreens emphasizes that the index measures relative illness activity, not disease severity. A higher score does not necessarily indicate more hospitalizations, more serious infections, or a greater risk of complications.
The index also does not represent a complete count of influenza cases nationwide.
Explore the interactive map:
https://www.walgreens.com/seasonal/respiratory-illness-index
Why Local Flu Activity Matters
Influenza does not spread evenly across the country.
Some communities may experience increasing cases weeks before others, making local information useful for families, schools, healthcare providers, and individuals who may be at higher risk of complications.
“Flu activity can vary significantly from one community to another, and knowing what’s happening locally can make a real difference,” said Rick Gates, Walgreens’ chief pharmacy and enterprise external affairs officer.
Gates added that the index is intended to help people make informed decisions about prevention, including vaccination before influenza becomes more widespread in their communities.
For residents of states such as Arizona, California, Nevada, and other western states, the reported regional increases make monitoring local respiratory illness trends particularly relevant.
However, the company’s announcement does not establish that every western county is experiencing elevated flu activity. Readers should consult the latest local data for a more accurate picture.
Why Getting a Flu Shot Still Matters
Annual influenza vaccination remains an important tool for reducing the risk of flu illness and serious complications.
Because influenza viruses change over time, flu vaccines are reviewed and updated each season to target strains expected to circulate.
The CDC recommends annual influenza vaccination for most people ages six months and older, with rare exceptions.
Vaccination is especially important for people who face a greater risk of serious complications, including:
- Adults ages 65 and older
- Young children, particularly those younger than five
- Pregnant individuals
- People with chronic conditions such as asthma, diabetes, or heart disease
- People with weakened immune systems
For adults 65 and older, the CDC preferentially recommends certain enhanced influenza vaccines, including higher-dose, recombinant, or adjuvanted options, when available.
Walgreens says its pharmacies offer standard-dose and higher-dose vaccines, along with a new mRNA influenza vaccine at select locations.
Vaccine selection should follow current CDC recommendations, individual eligibility, and guidance from a qualified healthcare professional.
It generally takes about two weeks after vaccination for the body to develop protective antibodies.
Even if influenza is already circulating locally, vaccination can still provide benefits throughout the season.
Practical Ways to Reduce Your Risk of Getting Sick
Vaccination is an important preventive measure, but it is not the only step people can take to reduce the spread of respiratory illnesses.
Public health guidance also encourages several everyday precautions.
Wash your hands regularly. Use soap and water, particularly after touching shared surfaces or being in public places. Alcohol-based hand sanitizer can help when soap and water are unavailable.
Cover coughs and sneezes. Use a tissue or your elbow to reduce the spread of respiratory droplets.
Improve indoor air quality. Opening windows when practical, improving ventilation, and using appropriate air filtration can help reduce exposure to airborne respiratory viruses.
Avoid close contact when sick. Staying home when experiencing respiratory illness symptoms can help protect coworkers, classmates, friends, and family members.
Consider wearing a well-fitting mask. Masks can provide an additional layer of protection, particularly in crowded indoor spaces or around people at higher risk.
Pay attention to symptoms. Fever, coughing, sore throat, fatigue, muscle aches, and congestion can occur with influenza and other respiratory infections.
Because flu and COVID-19 can produce similar symptoms, testing may help determine the cause of an illness.
People at higher risk of complications should contact a healthcare professional promptly if flu symptoms develop. Prescription antiviral medications work best when started early, ideally within the first two days of symptoms, although treatment can still benefit some patients later.
Walgreens Expands Vaccination Access for the 2026–2027 Season
Alongside the launch of its Flu Index, Walgreens announced several efforts to make seasonal vaccinations more convenient.
The company says it is increasing pharmacy staffing, expanding appointment availability, and allowing customers to schedule vaccinations further in advance.
Customers can arrange appointments through several methods:
- Online: https://www.walgreens.com/ScheduleVaccine
- Mobile: Walgreens app
- Text: Send “Flu” to 66879
- Telephone: 1-800-WALGREENS
- Walk-in: Participating Walgreens pharmacies, subject to availability
Walgreens also announced promotional Walgreens Cash rewards for eligible myWalgreens members receiving vaccinations.
Under the limited-time promotion, qualifying members may earn $15 in Walgreens Cash rewards on eligible purchases, along with an additional 10% back on qualifying purchases for a limited period.
Restrictions, exclusions, geographic limitations, and promotional deadlines apply. Customers should review the official terms before participating.
What About COVID-19 and Other Respiratory Illnesses?
Although influenza is the primary focus of the seasonal announcement, the Walgreens Flu Index also tracks COVID-19 and broader acute respiratory illness trends.
This distinction matters because several respiratory viruses can circulate simultaneously during the fall and winter months.
Influenza, COVID-19, respiratory syncytial virus (RSV), and common cold viruses can produce overlapping symptoms, but their potential complications and recommended treatments differ.
Vaccination eligibility and recommendations also vary by disease, age, and individual health circumstances.
Readers should consult current CDC guidance and their healthcare providers when considering flu, COVID-19, or RSV vaccination.
The Bottom Line: Flu Season May Be Early, but Prevention Still Matters
The launch of the 2026–2027 Walgreens Flu Index offers another resource for Americans who want to monitor respiratory illness activity in their communities.
While Walgreens’ early findings suggest influenza activity is increasing sooner than in recent years, it is still too early to determine how severe the overall season will become.
The most important message for consumers is to prepare before respiratory illnesses become widespread.
Staying current with recommended vaccinations, practicing good hygiene, monitoring local illness trends, and seeking medical attention when appropriate can help reduce the risk of serious illness.
With flu activity already rising in some regions, now is a good time for families to review their seasonal health plans.
Related Links for Further Information
Walgreens Resources
- Walgreens Respiratory Illness Index — Interactive map showing respiratory illness activity across the United States.
- Walgreens Vaccination Scheduling — Schedule a flu vaccination or explore available vaccines.
Public Health Resources
- CDC Seasonal Influenza Information — Information about influenza symptoms, prevention, vaccination, and treatment.
- CDC FluView Surveillance — National influenza surveillance and weekly activity reports.
- CDC: Flu and People 65 Years and Older — Guidance for older adults and influenza vaccination.
- CDC Respiratory Illnesses — Prevention information for flu, COVID-19, and RSV.
Source: Walgreen Co., press release, October 21, 2026, Walgreens Launches 2026–2027 Flu Index as Activity Tracks Four Weeks Ahead of Recent Seasons.
Editor’s Note: This article summarizes information from Walgreens’ October 21, 2026, announcement. The reported early-season trends reflect the company’s findings at that time and are not a substitute for current CDC surveillance or medical advice. Readers should consult healthcare professionals about individual vaccination and treatment decisions.
STM Daily News — News You Can Use This Moment!
